Access of patients with breast and lung cancer to chemotherapy treatment in public and private hospitals in the city of Buenos Aires

Author:

Recondo Gonzalo1ORCID,Cosacow César2,Cutuli Hernán Javier3,Cermignani Luciano4,Straminsky Samanta5,Naveira Martin6,Pitzzu Martin7,De Ronato Gabriela5,Nacuzzi Gabriela7,Taetti Gonzalo3,Corsico Santiago6,Berrueta Mabel8,Colucci Giuliana2,Gibbons Luz8,Gutierrez Laura8,García-Elorrio Ezequiel9ORCID

Affiliation:

1. Medical Oncology, Centro de Educación Médica e Investigaciones Clínicas ‘Norberto Quirno’ (CEMIC), Buenos Aires, Argentina

2. Instituto Universitario CEMIC, Buenos Aires, Argentina

3. Medical Oncology, Instituto de Oncología Ángel H. Roffo, Buenos Aires, Argentina

4. Medical Oncology, Hospital Alemán de Buenos Aires, Buenos Aires, Argentina

5. Medical Oncology, Hospital General de Agudos ‘Dr. Juan A. Fernández’, Buenos Aires, Argentina

6. Medical Oncology, Hospital Británico de Buenos Aires. Buenos Aires, Argentina

7. Medical Oncology, Hospital General de Agudos ‘Carlos G. Durand’, Buenos Aires, Argentina

8. Data Unit, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

9. Quality of Care and Patient Safety Department, Institute for Clinical Effectiveness and Health Policy (IECS)

Abstract

Abstract Objectives Describe the time elapsed from the diagnosis to treatment with chemotherapy for patients with breast and lung cancer at public and private hospitals in Buenos Aires. Design Retrospective cohort study. Setting Three public and three private academic hospitals in Buenos Aires. Participants Patients with breast (n = 168) or lung cancer (n = 100) diagnosis treated with chemotherapy. Main outcomes measures Clinical and sociodemographic data were collected in a stratified sample. We used the Kaplan–Meier estimator to analyse the time elapsed and the log rank test to compare both groups Results For breast cancer patients, median time elapsed between diagnosis and treatment with chemotherapy was 76 days (95% CI: 64–86) in public and 60 days (95% CI: 52–65) in private hospitals (P = 0.0001). For adjuvant and neoadjuvant treatments, median time was 130 (95% CI: 109–159) versus 64 (95% CI: 56–73) days (P < 0.0001) and 57 days (95% CI: 49–75) versus 26 (95% CI: 16–41) days, respectively (P = 0.0002). There were no significant differences in the time from first consultation to diagnosis. In patients with lung cancer, median time from diagnosis to treatment was 71 days (95% CI: 60–83) in public hospitals and 31 days (95% CI: 24–39) in private hospitals (P = 0.0002). In the metastatic setting, median time to treatment was 63 days (95% CI: 45–83) in public and 33 (95% CI: 26–44) days in private hospitals (P = 0.005). Conclusions There are significant disparity in the access to treatment with chemotherapy for patients in Buenos Aires, Argentina.

Funder

National Cancer Institute of Argentina

Publisher

Oxford University Press (OUP)

Subject

Public Health, Environmental and Occupational Health,Health Policy,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3